Drug Trial Radar · NCT07170995
Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
460
Planned (sponsor's estimate)
Start
Oct 22, 2025
Primary completion
Dec 2030
Study completion Dec 2030
Sponsor
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Sep 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a randomized, open-label, controlled, multicenter Phase III clinical trial to evaluate the efficacy and safety of SHR-8068 combined with adebrelimab and platinum-based chemotherapy versus tislelizumab combined with platinum-based chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer.
Conditions
- Advanced or Metastatic Non-small Cell Lung Cancer
Interventions
SHR-8068,adebelizumab and platinum-based chemotherapyDrug
SHR-8068,adebelizumab and platinum-based chemotherapy
tislelizumab, and platinum-based chemotherapyDrug
tislelizumab, and platinum-based chemotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-Free Survival (PFS) by Blinded Independent Central Review [BICR]Time frame: Approximately 32 months.
- OSTime frame: Approximately 64 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Affiliated Cancer Hospital of Shandong First Medical University
Jinan, Shandong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.